186 related articles for article (PubMed ID: 24480856)
1. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.
Jung JW; Kang HR; Lee SH; Cho SH
Oncology; 2014; 86(3):127-34. PubMed ID: 24480856
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.
Hong J; Kim JY; Ahn HK; Lee SM; Sym SJ; Park J; Cho EK; Ahn JY; Park S; Lee SP; Shin DB; Lee JH
Support Care Cancer; 2013 Apr; 21(4):1145-52. PubMed ID: 23111943
[TBL] [Abstract][Full Text] [Related]
3. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.
Hayama T; Miura K; Uchiike A; Nakagawa M; Tsutsumi D; Sakagami M; Yoshida Y; Takei M
Int J Clin Pharm; 2017 Apr; 39(2):380-385. PubMed ID: 28144804
[TBL] [Abstract][Full Text] [Related]
4. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
5. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.
Pritchard CH; Greenwald MW; Kremer JM; Gaylis NB; Rigby W; Zlotnick S; Chung C; Jaber B; Reiss W;
BMC Musculoskelet Disord; 2014 May; 15():177. PubMed ID: 24884454
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular adverse events complicating the administration of rituximab: report of two cases.
Passalia C; Minetto P; Arboscello E; Balleari E; Bellodi A; Del Corso L; Molinari E; Ponassi I; Oneto C; Sicbaldi V; Ghio R
Tumori; 2013; 99(6):288e-92e. PubMed ID: 24503806
[TBL] [Abstract][Full Text] [Related]
7. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Pei SN; Ma MC; Wang MC; Kuo CY; Rau KM; Su CY; Chen CH
Ann Hematol; 2012 Jul; 91(7):1007-12. PubMed ID: 22273839
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
Hopps S; Medina P; Pant S; Webb R; Moorman M; Borders E
J Oncol Pharm Pract; 2013 Sep; 19(3):222-7. PubMed ID: 23135806
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and safety of rituximab (MabThera).
Kimby E
Cancer Treat Rev; 2005 Oct; 31(6):456-73. PubMed ID: 16054760
[TBL] [Abstract][Full Text] [Related]
10. Use of a pharmacy protocol to convert standard rituximab infusions to rapid infusion shortens outpatient infusion clinic visits.
Swan JT; Zaghloul HA; Cox JE; Murillo JR
Pharmacotherapy; 2014 Jul; 34(7):686-94. PubMed ID: 24706572
[TBL] [Abstract][Full Text] [Related]
11. Incidence of infusion-related reaction to monoclonal antibody rituximab: a national kidney and transplant institute experience.
Montoya JE; Luna HG; Vergara NG; Amparo JR; Cristal-Luna GR
Ann Acad Med Singap; 2012 Mar; 41(3):125-6. PubMed ID: 22538739
[No Abstract] [Full Text] [Related]
12. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
13. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
14. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
15. A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma.
Tsutsumi D; Hayama T; Miura K; Uchiike A; Tsuboi S; Otsuka S; Hatta Y; Kishikawa Y
Int J Clin Pharm; 2022 Apr; 44(2):366-373. PubMed ID: 34894347
[TBL] [Abstract][Full Text] [Related]
16. Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients.
Kang HJ; Park JS; Kim DW; Lee J; Jeong YJ; Choi SM; Lee SM; Yang SC; Yoo CG; Kim YW; Han SK; Yim JJ
Respir Med; 2012 Mar; 106(3):443-50. PubMed ID: 22154502
[TBL] [Abstract][Full Text] [Related]
17. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
Bonnekoh B; Schulz M; Franke I; Gollnick H
J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
[TBL] [Abstract][Full Text] [Related]
18. Rapid development of infusion-related severe hypotension during rituximab therapy.
Vo KH; Waddell JA; Suda KJ
Ann Pharmacother; 2011 May; 45(5):e29. PubMed ID: 21505107
[TBL] [Abstract][Full Text] [Related]
19. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
Tobinai K
Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
[TBL] [Abstract][Full Text] [Related]
20. [Subcutaneous Rituximab is effective and safe].
Häckel A
Med Monatsschr Pharm; 2014 Jan; 37(1):39-40. PubMed ID: 24490439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
